<DOC>
	<DOCNO>NCT00659477</DOCNO>
	<brief_summary>Aim study compare two treatment regimen ( insulin Lantus basal insulin v insulin NPH ) plus oral antidiabetic type 2 diabetic patient confirm superiority insulin glargine . Comparison focus : blood glucose ( BG ) variability two treatment regimen , quality diabetes compensation ( HbA1c , FBG/Fasting blood glucose ) , body weight development , dose insulin occurrence symptomatic hypoglycaemia adverse event .</brief_summary>
	<brief_title>Comparison Safety Efficacy Basal Insulin LantusÂ® ( Insulin Glargine ) v NPH Insulin Combination With Oral Antidiabetic Drugs ( OADs ) Patients With Diabetes Mellitus , Type 2 ( DMT2 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<criteria>Diabetes type 2 Patients treat NPH insulin stable dosage OADs ( Oral antidiabetic drug ) least 2 month prior study start OADs treatment metformin least 1,7 g /day combination sulfonylurea glinides . Patients must HbA1c range &gt; = 4,5 % ( 6,2 % DCCT/Diabetes Control Complication Trials ) &lt; = 8 % ( 9,4 % DCCT/Diabetes Control Complication Trials ) Ability willingness perform continuous glucose monitoring system / CGMS ( examination within study ) Written informed consent obtain prior enrollment study Women either childbearing potential woman childbearing potential must pregnant must use reliable contraceptive measure duration study 1 . Fasting value C peptide &lt; = 400 pmol/l 2 . Active proliferative diabetic retinopathy , define application photocoagulation surgery , 6 month study entry unstable rapidly progress retinopathy may require photocoagulation surgery study . 3 . Pregnant woman woman plan gravidity clinical study protocol 4 . Breastfeeding 5 . History hypersensitivity study drug drug similar chemical structure 6 . Treatment systemic corticosteroid 3 month prior study entry study treatment , significantly impression glycaemia . 7 . Likelihood require treatment study period drug permit clinical study protocol 8 . Clinically relevant cardiovascular , hepatic , neurological , endocrine , major disease make implementation protocol interpretation study result difficult 9 . Impaired hepatic function show Alamine aminotransferase ( ALT ) and/or Aspartate aminotransferase ( AST ) great three time upper limit normal range study entry 10 . Impaired renal function show serum creatinine &gt; /= 133 micromol/L men &gt; /= 124 micromol/L woman study entry 11 . History drug alcohol abuse last year 12 . Mental condition cause patient unable understand nature , scope possible consequence study 13 . Patient unlikely comply protocol , e.g. , uncooperative attitude , inability return followup visit unlikelihood complete study 14 . Use insulin glargine outside scope current SPC ( Summary Product Characteristics ) 16 . Patients include clinical study The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>